Value-Based Contracting and Specialty Pharmaceuticals: ...

October 19, 2021

Value-Based Contracting and Specialty Pharmaceuticals: A Synthesis of Implications from Key Opinion Leaders (KOLs)

Drug developers no longer have FDA approval as their top concern. Now payer coverage, access and reimbursements are the primary concern. Payer resistance to pay for treatment failures is growing when individual patient specialty drug therapy costs are $200k-$2+m. Meanwhile, specialty pharmaceuticals are expected to increase to >50% of total US drug expenditure by 2022. How has value-based contracting been impacting this high stakes challenge and what is in store for the future?

Click here to access the Quality Innovation Series registration page to register or review the full course content.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 PCMH CCE
Course opens: 
Course expires: 
Event starts: 
10/19/2021 - 1:00pm
Event ends: 
10/19/2021 - 2:00pm

Jordana Barona, MBA, MPH
Product Development Manager, NCQA


Scott J. Kornhauser
SJ Kornhauser Consulting

This live course grants 1.0  Continuing Education Unit (CEU) points for PCMH Certified Content Experts.  

* Please note – You must attend the entire program to be eligible for total number of contact hours.

Available Credit

  • 1.00 Participation
  • 1.00 PCMH CCE


Please login or register to take this course.